NASDAQ:TRVN - Trevena Stock Price, Price Target & More

$1.73 -0.02 (-1.14 %)
(As of 04/23/2018 01:27 AM ET)
Previous Close$1.73
Today's Range$1.71 - $1.75
52-Week Range$1.34 - $3.64
Volume333,652 shs
Average Volume700,324 shs
Market Capitalization$115.83 million
P/E Ratio-1.43
Dividend YieldN/A
Beta-0.52

About Trevena (NASDAQ:TRVN)

Trevena logoTrevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840

Debt

Debt-to-Equity Ratio0.45%
Current Ratio3.71%
Quick Ratio3.71%

Price-To-Earnings

Trailing P/E Ratio-1.43
Forward P/E Ratio-1.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.75 million
Price / Sales30.89
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book3.09

Profitability

EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-140.68%
Return on Assets-81.64%

Miscellaneous

Employees51
Outstanding Shares66,950,000

How to Become a New Pot Stock Millionaire

Trevena (NASDAQ:TRVN) Frequently Asked Questions

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena Inc (NASDAQ:TRVN) announced its earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. View Trevena's Earnings History.

When is Trevena's next earnings date?

Trevena is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Trevena.

What price target have analysts set for TRVN?

6 brokerages have issued 1 year target prices for Trevena's stock. Their predictions range from $2.50 to $10.00. On average, they expect Trevena's stock price to reach $6.75 in the next year. View Analyst Ratings for Trevena.

What are Wall Street analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:
  • 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (1/20/2018)
  • 2. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)

Who are some of Trevena's key competitors?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:
  • Leon O. Moulder Jr., Independent Chairman of the Board (Age 59)
  • Maxine Gowen Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Roberto E. Cuca, Chief Financial Officer, Senior Vice President (Age 49)
  • Carrie L. Bourdow, Chief Operating Officer, Executive Vice President (Age 55)
  • John M. Limongelli Esq., Chief Administrative Officer, Senior Vice President, General Counsel, Secretary (Age 47)
  • Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning (Age 49)
  • David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer (Age 49)
  • Michael R. Dougherty, Independent Director (Age 59)
  • Adam M. Koppel M.D. Ph.D., Independent Director (Age 47)
  • Julie H. McHugh, Independent Director (Age 52)

Has Trevena been receiving favorable news coverage?

News coverage about TRVN stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trevena earned a media sentiment score of 0.10 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.73.

How big of a company is Trevena?

Trevena has a market capitalization of $115.83 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]


MarketBeat Community Rating for Trevena (TRVN)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  390 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  515
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trevena (NASDAQ:TRVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Trevena in the last 12 months. Their average twelve-month price target is $6.75, suggesting that the stock has a possible upside of 290.17%. The high price target for TRVN is $10.00 and the low price target for TRVN is $2.50. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.862.902.92
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.75$7.7857$8.65$10.2083
Price Target Upside: 290.17% upside337.40% upside385.96% upside366.13% upside

Trevena (NASDAQ:TRVN) Consensus Price Target History

Price Target History for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2018OppenheimerReiterated RatingBuyLowView Rating Details
3/8/2018HC WainwrightBoost Price TargetBuy$7.00HighView Rating Details
11/8/2017Needham & Company LLCLower Price TargetBuy$9.00 -> $7.00N/AView Rating Details
10/16/2017BarclaysDowngradeOverweight -> Equal Weight$15.00 -> $2.50N/AView Rating Details
8/4/2017CowenReiterated RatingBuy$10.00MediumView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
4/17/2017AegisReiterated RatingBuy$14.00LowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$8.00HighView Rating Details
2/16/2017Jefferies GroupReiterated RatingBuy$11.00N/AView Rating Details
2/2/2017Ladenburg ThalmannInitiated CoverageBuy$15.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00N/AView Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Trevena (NASDAQ:TRVN) Earnings History and Estimates Chart

Earnings by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.21)($0.16)($0.18)
Q2 20183($0.20)($0.16)($0.18)
Q3 20183($0.22)($0.16)($0.20)
Q4 20183($0.23)($0.16)($0.21)

Trevena (NASDAQ TRVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.22)N/AView Earnings Details
3/7/2018Q4 2017($0.26)($0.24)ViewListenView Earnings Details
11/7/2017Q3 2017($0.33)($0.27)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.35)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.55)($0.36)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.62)($0.67)$0.48 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.40)($0.57)$1.90 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.35)($0.37)$1.89 million$1.88 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)$1.93 million$1.88 millionViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)$1.80 million$1.88 millionViewN/AView Earnings Details
8/11/2015Q215($0.3680)($0.28)$1.30 million$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)$10.00 million$0.63 millionViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.0412 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Trevena (NASDAQ:TRVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Trevena (NASDAQ TRVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 48.83%
Insider Trading History for Trevena (NASDAQ:TRVN)
Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ TRVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/22/2018Yacoub HabibSVPSell5,000$1.76$8,800.00View SEC Filing  
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.0016,500View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.005,000View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08279,025View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.351,750View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Trevena (NASDAQ TRVN) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect Trevena Inc (TRVN) to Post -$0.19 EPSZacks: Analysts Expect Trevena Inc (TRVN) to Post -$0.19 EPS
www.americanbankingnews.com - April 16 at 5:15 AM
Trevena (TRVN) PT Set at $8.00 by OppenheimerTrevena (TRVN) PT Set at $8.00 by Oppenheimer
www.americanbankingnews.com - April 13 at 10:53 AM
BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018
www.reuters.com - April 13 at 8:20 AM
Form 8-K TREVENA INC For: Apr 09Form 8-K TREVENA INC For: Apr 09
www.streetinsider.com - April 12 at 5:38 PM
Barclays Lowers Trevena (TRVN) to Equal WeightBarclays Lowers Trevena (TRVN) to Equal Weight
www.americanbankingnews.com - April 7 at 10:53 AM
Zacks Investment Research Upgrades Trevena (TRVN) to "Buy"Zacks Investment Research Upgrades Trevena (TRVN) to "Buy"
www.americanbankingnews.com - April 6 at 3:01 PM
BRIEF-Trevena Announces Retirement Of Maxine Gowen, Ph.D., Effective October 1, And Planned Promotion Of Carrie ...BRIEF-Trevena Announces Retirement Of Maxine Gowen, Ph.D., Effective October 1, And Planned Promotion Of Carrie ...
www.reuters.com - April 5 at 5:17 PM
Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L ...Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L ...
globenewswire.com - April 5 at 5:17 PM
Trevena (TRVN) CEO Maxine Gowen to Retire; Announces Planned Promotion of Carrie L. Bourdow to President and ...Trevena (TRVN) CEO Maxine Gowen to Retire; Announces Planned Promotion of Carrie L. Bourdow to President and ...
www.streetinsider.com - April 5 at 5:17 PM
Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive OfficerTrevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer
finance.yahoo.com - April 5 at 5:17 PM
Founding CEO of Trevena biopharm firm to retireFounding CEO of Trevena biopharm firm to retire
finance.yahoo.com - April 5 at 5:17 PM
Trevena Inc (TRVN) Given Average Rating of "Buy" by BrokeragesTrevena Inc (TRVN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 3:25 AM
Zacks Investment Research Lowers Trevena (TRVN) to HoldZacks Investment Research Lowers Trevena (TRVN) to Hold
www.americanbankingnews.com - April 2 at 8:21 AM
Needham & Company LLC Trims Trevena (TRVN) Target Price to $7.00Needham & Company LLC Trims Trevena (TRVN) Target Price to $7.00
www.americanbankingnews.com - April 1 at 10:29 AM
Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMTEdited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT
finance.yahoo.com - April 1 at 8:23 AM
-$0.19 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter-$0.19 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - March 30 at 9:34 AM
Trevenas (TRVN) "Buy" Rating Reiterated at OppenheimerTrevena's (TRVN) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM
Trevena to Present at the Needham & Company 17th Annual Healthcare ConferenceTrevena to Present at the Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 20 at 5:16 PM
Trevena (TRVN) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowTrevena (TRVN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:11 PM
Oppenheimer Analysts Lift Earnings Estimates for Trevena Inc (TRVN)Oppenheimer Analysts Lift Earnings Estimates for Trevena Inc (TRVN)
www.americanbankingnews.com - March 15 at 8:45 AM
Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare ConferenceTrevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 7:06 PM
Oppenheimer Weighs in on Trevena Incs FY2022 Earnings (TRVN)Oppenheimer Weighs in on Trevena Inc's FY2022 Earnings (TRVN)
www.americanbankingnews.com - March 14 at 4:24 PM
Trevena Inc (TRVN) Expected to Announce Earnings of -$0.20 Per ShareTrevena Inc (TRVN) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 13 at 5:12 AM
Trevena (TRVN) Given a $5.00 Price Target at OppenheimerTrevena (TRVN) Given a $5.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 12 at 7:10 PM
Trevena Inc to Post FY2018 Earnings of ($0.85) Per Share, Jefferies Group Forecasts (TRVN)Trevena Inc to Post FY2018 Earnings of ($0.85) Per Share, Jefferies Group Forecasts (TRVN)
www.americanbankingnews.com - March 12 at 4:22 AM
Trevena Inc (TRVN) Given Average Recommendation of "Buy" by AnalystsTrevena Inc (TRVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 10 at 4:14 AM
Trevena Inc (TRVN) Forecasted to Post Q1 2018 Earnings of ($0.21) Per ShareTrevena Inc (TRVN) Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - March 9 at 8:53 AM
HC Wainwright Boosts Trevena (TRVN) Price Target to $7.00HC Wainwright Boosts Trevena (TRVN) Price Target to $7.00
www.americanbankingnews.com - March 8 at 11:04 PM
Trevena (TRVN) Posts  Earnings Results, Beats Estimates By $0.03 EPSTrevena (TRVN) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 8 at 9:04 AM
Trevena, Inc. to Host Earnings CallTrevena, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM
Trevena Reports Full Year 2017 EarningsTrevena Reports Full Year 2017 Earnings
finance.yahoo.com - March 7 at 6:33 PM
Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?
finance.yahoo.com - March 7 at 6:33 PM
Trevena to Present at the Cowen and Company 38th Annual Healthcare ConferenceTrevena to Present at the Cowen and Company 38th Annual Healthcare Conference
finance.yahoo.com - March 7 at 6:33 PM
Trevena Reports Full Year 2017 Earnings - GlobeNewswire (press release)Trevena Reports Full Year 2017 Earnings - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:19 AM
Head-To-Head Review: Trevena (TRVN) versus Edge Therapeutics (EDGE)Head-To-Head Review: Trevena (TRVN) versus Edge Therapeutics (EDGE)
www.americanbankingnews.com - March 3 at 10:34 AM
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 2 at 6:09 PM
Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results - GlobeNewswire (press release)Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 28 at 8:18 AM
Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial ResultsTrevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 8:18 AM
Trevena (TRVN) to Release Quarterly Earnings on TuesdayTrevena (TRVN) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
-$0.26 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter-$0.26 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - February 24 at 8:06 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem - PR Newswire (press release)
www.prnewswire.com - February 21 at 8:23 AM
Trevena Inc (TRVN) Receives Consensus Recommendation of "Buy" from AnalystsTrevena Inc (TRVN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 13 at 3:30 AM
Head to Head Comparison: Denali Therapeutics (DNLI) and Trevena (TRVN)Head to Head Comparison: Denali Therapeutics (DNLI) and Trevena (TRVN)
www.americanbankingnews.com - February 8 at 5:22 PM
 Brokerages Expect Trevena Inc (TRVN) to Announce -$0.26 EPS Brokerages Expect Trevena Inc (TRVN) to Announce -$0.26 EPS
www.americanbankingnews.com - February 7 at 9:52 AM
Trevena (TRVN) Promotes Carrie Bourdow to Executive Vice President and COO - StreetInsider.comTrevena (TRVN) Promotes Carrie Bourdow to Executive Vice President and COO - StreetInsider.com
www.streetinsider.com - February 3 at 9:31 AM
Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating OfficerTrevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating Officer
finance.yahoo.com - February 2 at 9:31 AM
Trevena (TRVN) Rating Lowered to Hold at Zacks Investment ResearchTrevena (TRVN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 20 at 8:22 PM
7 High-Risk, High-Reward Stocks to Buy Now7 High-Risk, High-Reward Stocks to Buy Now
finance.yahoo.com - January 19 at 9:07 AM
Trevena (TRVN) versus The Competition Head-To-Head AnalysisTrevena (TRVN) versus The Competition Head-To-Head Analysis
www.americanbankingnews.com - January 16 at 7:56 PM
Head to Head Analysis: Trevena (TRVN) and Its RivalsHead to Head Analysis: Trevena (TRVN) and Its Rivals
www.americanbankingnews.com - January 12 at 3:28 PM

SEC Filings

Trevena (NASDAQ:TRVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Trevena (NASDAQ:TRVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Trevena (NASDAQ TRVN) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.